COMPANY · BIOTECH

EnteroBiotix

Profile checked Oct 12, 2026

EnteroBiotix is a clinical-stage microbiome company developing EBX-102-02, an oral full-spectrum microbiome drug for irritable bowel syndrome (IBS) and other diseases linked to the gut and liver. A Phase 2 trial in IBS is registered. Source

Sources: Company website · ISRCTN registry · Company website (checked Oct 12, 2026)

Keywords: microbiome IBS gastrointestinal liver EBX-102-02 Scotland UK gastroenterology irritable bowel syndrome oncology liver cirrhosis hematologic cancer

Website: enterobiotix.com · Trial: ISRCTN15681288 · Careers: not checked yet

Type: Biotech (therapeutics)
Stage: Phase 2
Location: Bellshill, UK

Funding and NIH signals

SEC Form D raise Raised $5.34M (Form D filed Apr 9, 2026). SEC Form D 0001104659-26-041397 (Apr 9, 2026)
Evidence (1 event)
- Apr 9, 2026 · SEC Form D 0001104659-26-041397
  Name of Issuer: EnteroBiotix LTD; CIK: 1946072; Address: Glasgow, United Kingdom; Submission type: D; Filing date: 2026-04-09; Industry Group: Biotechnology; Date of First Sale: 2026-03-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 5341593; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals